Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.83 USD | -1.08% |
|
+12.96% | -87.57% |
24/06 | Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from S&P Pharmaceuticals Select Industry Index | CI |
21/06 | Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar | RE |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.39 for the 2024 fiscal year.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-87.57% | 124M | - | ||
+2.97% | 94.74B | A- | ||
-4.08% | 37.28B | A- | ||
-13.26% | 32.68B | B- | ||
+74.21% | 27.72B | A | ||
-11.58% | 16.19B | C | ||
-1.66% | 13.88B | B- | ||
-11.67% | 11.58B | D+ | ||
+190.36% | 10.92B | D | ||
-52.61% | 9.54B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AMLX Stock
- Ratings Amylyx Pharmaceuticals, Inc.